Guangda Securities: Maintains a "Buy" rating on Mediland Medical Healthcare (02373.HK) with a 1.2 billion Hong Kong dollar large shareholder return plan to solidify confidence.

According to the Zhixing Finance and Economics APP, Guotai Junan Securities released a research report stating that considering the acquisition of Siyanli will directly increase the company's performance, they have raised the net profit attributable to the parent company of Meili Tianyuan Medical Health (02373.HK) to 3.2/4.4/4.9 billion yuan for the years 2025-2027 (increases of 5%/26%/21% respectively), with corresponding EPS of 1.36/1.86/2.09 yuan. The current stock price corresponds to PE ratios of 20, 14, and 13 times respectively. As a leading company in China's beauty and medical aesthetics industry, the company's long-term performance growth is clear, the company places a high value on shareholder returns, and they maintain a "buy" rating.